In recent years, homologous recombination deficiency (HRD) has not achieved the expected substantial promotion of immunotherapeutic efficacy in
ovarian cancer. This study aims to explore the role of HRD functional phenotype as a powerful
biomarker in identifying HRD patients who may benefit from
immunotherapy. HRD functional phenotype, namely HRD-EXCUTE, was defined as the average level of the 15 hub genes upregulated in HRD
ovarian cancer. A decision tree was plotted to evaluate the critical role of HRD-EXCUTE in HRD patients. Agents inducing HRD-EXCUTE were identified by CMAP web (Connectivity Map). The mechanisms and immunotherapeutic effect of PARPi and HDACi in promoting HRD-EXCUTE was examined in vitro and in vivo. The decision tree plotted on the basis of HRD and HRD-EXCUTE indicated the HRD patients without the HRD functional phenotype were largely unresponsive to
immunotherapy, which was validated by the immunotherapeutic cohorts. Furthermore, loss of HRD-EXCUTE in the HRD patients attenuated immunogenicity and inhibited immune cells in tumor microenvironment. Moreover,
Niraparib combined with
Entinostat induced HRD-EXCUTE by activating the cGAS-
STING pathway and increasing the
histone acetylation. The combination
therapy could enhance the cytotoxicity of immune cells, and promote pro-immune cells infiltrating into
ascites, resulting in inhibited
ovarian cancer growth. The HRD functional phenotype HRD-EXCUTE was set up as a potent
biomarker to identify whether HRD patients can benefit from
immunotherapy. Loss of HRD-EXCUTE in HRD patients were largely insensitive to
immunotherapy. The combination of PARPi with HDACi could improve the efficacy of the PARPi-based
immunotherapy in
ovarian cancer by augmenting the HRD functional phenotype.